Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997

Chest

Volumn 119, Issue 5, 2001, Pages 1420-1426

  Houck, P M ^a   MacLehose, R F ^a   Niederman, M S ^b   Lowery, J K ^a  

^a Health Care Financing Administration   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Atypical pathogen; Community acquired; Macrolide; Mortality; Pneumonia

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; COMMUNITY; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VIRUS PNEUMONIA;

EID: 0034939765     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.5.1420     Document Type: Article

References (31)

1. Predicting hospital-associated mortality for Medicare patients: A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure
2. Prognosis of patients hospitalized with community-acquired pneumonia
3. Prognosis and outcome of patients with community-acquired pneumonia: A meta-analysis
4. A prediction rule to identify low-risk patients with community-acquired pneumonia
5. Effects of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
6. Implications for macrolide treatment in community-acquired pneumonia
7. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
8. Microbial etiology of acute pneumonia in hospitalized patients
9. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors
10. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
11. Community-acquired pneumonia in old age: A prospective study of 91 patients admitted from home
12. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients
13. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A 1-year prospective study of 346 consecutive patients
14. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
15. Community-acquired pneumonia: Impact of immune status
16. Etiology in community-acquired pneumonia: Incidence of combined typical and atypical pathogens
17. Community-acquired pneumonia in the ICUs
18. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
19. Community-acquired pneumonia in adults: Guidelines for management
20. Practice guidelines for the management of community-acquired pneumonia in adults
21. New macrolides or new quinolones as monotherapy for patients with community-acquired pneumonia: Our cup runneth over?
22. An epidemic of infections because of Chlamydia pneumoniae in military conscripts
23. Surveillance for legionnaires' disease: Risk factors for morbidity and mortality
24. Summary of notifiable diseases, United States 1997
25. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
26. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
27. Prevalence of antimicrobial drug-resistant Streptococcus pneumoniae in Washington State